A Study of ATG-031 in Advanced Solid Tumors or B-cell Non-Hodgkin Lymphomas

Stopped early · Phase 1

Conditions studied: Advanced Solid Tumors, B-cell Non-Hodgkin Lymphomas

In brief

ATG-031 study (alias: PERFORM) is a multicenter, open-label, Phase 1 study of ATG-031 in patients with advanced solid tumors or B-NHL. The study design includes a Dose Escalation Phase and a Dose Expansion Phase, and will enroll patients with advanced solid tumors (i.e., preferred tumor types) or relapsed/refractory (R/R) B-NHLs. The study's primary objective is to evaluate the safety and tolerability of ATG-031 and determine the RP2D（Refered Phase II dose） of ATG-031.

Key facts

Study ID

NCT06028373

Run by

Antengene Biologics Limited

People needed

38

Starts

2023-12-08

Expected to finish

2026-06-12

Last updated by the study team

2026-07-16

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• University of California San Francisco (UCSF) — San Francisco, California, United States
• Regents of the University of Colorado — Aurora, Colorado, United States
• Yale University — New Haven, Connecticut, United States
• University of Texas M.D. Anderson Cancer Center — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.